Connor, Clark & Lunn Investment Management Ltd. Enanta Pharmaceuticals Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.1 Billion
- Q1 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 30,465 shares of ENTA stock, worth $219,652. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,465
Previous 24,636
23.66%
Holding current value
$219,652
Previous $141,000
19.15%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ENTA
# of Institutions
112Shares Held
18.8MCall Options Held
5.6KPut Options Held
13.9K-
Farallon Capital Management LLC San Francisco, CA2.12MShares$15.3 Million0.07% of portfolio
-
Krensavage Asset Management, LLC New York, NY2.12MShares$15.3 Million6.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.01MShares$14.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.85MShares$13.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.35MShares$9.71 Million0.0% of portfolio
About ENANTA PHARMACEUTICALS INC
- Ticker ENTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,724,900
- Market Cap $149M
- Description
- Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...